Accessibility Menu
Guardant Health Stock Quote

Guardant Health (NASDAQ: GH)

$68.05
(0.8%)
+0.54
Price as of October 22, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$68.05
Daily Change
(0.8%) +$0.54
Day's Range
$66.83 - $69.46
Previous Close
$68.05
Open
$69.4
Beta
1.68
Volume
68,956
Average Volume
2,583,641
Market Cap
8.5B
Market Cap / Employee
$68.03M
52wk Range
$20.14 - $70.33
Revenue
-
Gross Margin
0.63%
Dividend Yield
N/A
EPS
-$3.35
CAPs Rating
-
Industry
Healthcare Providers and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Guardant Health Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
GH+223.94%-34.26%-8.05%+110%
S&P+14.5%+93.32%+14.09%+131%

Guardant Health Company Info

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

News & Analysis

The Fool has written over 100 articles on Guardant Health.

Financial Health

General

Q2 2025YOY Change
Revenue$232.09M30.9%
Gross Profit$150.88M44.0%
Gross Margin65.01%5.9%
Market Cap$6.45B82.4%
Market Cap / Employee$3.19M0.0%
Employees2K13.6%
Net Income-$99.90M2.7%
EBITDA-$96.41M-7.2%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$629.14M-39.2%
Accounts Receivable$130.25M29.6%
Inventory84.125.5%

Liabilities

Q2 2025YOY Change
Long Term Debt$1.31B-0.4%
Short Term Debt$26.28M-5.0%

Ratios

Q2 2025YOY Change
Return On Assets-28.14%0.3%
Return On Invested Capital-29.65%-5.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$66.09M33.3%
Operating Free Cash Flow-$60.44M35.7%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-47.01-62.61-37.83-25.66-149.81%
Price to Sales4.085.126.827.7941.87%
Price to Tangible Book Value-40.00-53.27-35.29-24.71-139.84%
Enterprise Value to EBITDA-29.64-37.02-58.38-74.3073.89%
Return on Equity-3883.9%-337.2%-609.3%-4584.5%946.38%
Total Debt$1.34B$1.34B$1.31B$1.33B-0.52%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.